Skip to main content
SpringerLink
Log in

ADRs due to off-label use of hydroxychloroquine for COVID-19

  • Clinical study
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Reference

  • Safety profile of hydroxychloroquine used off-label for the treatment of patients with COVID-19: A descriptive study based on Eudravigilance data Fundamental and Clinical Pharmacology : 12 May 2022. Available from: URL: https://doi.org/10.1111/fcp.12797

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

ADRs due to off-label use of hydroxychloroquine for COVID-19. Reactions Weekly 1907, 3 (2022). https://doi.org/10.1007/s40278-022-15262-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-022-15262-1

Search

Navigation